Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

NCT05987332 is registered in ClinicalTrials.gov with IDEAYA Biosciences as lead sponsor.

NCT NCT05987332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05987332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
Lead sponsor
IDEAYA Biosciences
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
October 31, 2023
Completion date
January 15, 2028
Enrollment
420 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma